STOCK TITAN

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

ALX Oncology (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing immune-boosting cancer therapies, has announced it will release its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. The company, which aims to treat cancer and extend patients' lives, noted that there will not be a teleconference accompanying the financial results press release.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+0.94%
1 alert
+0.94% News Effect

On the day this news was published, ALXO gained 0.94%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. 

The company will not be hosting a teleconference in conjunction with its financial results press release.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577


FAQ

When will ALX Oncology (ALXO) release its Q4 and full year 2024 earnings?

ALX Oncology will release its Q4 and full year 2024 financial results on March 6th, 2025, before market open.

Will ALXO host an earnings call for Q4 2024 results?

No, ALX Oncology will not be hosting a teleconference in conjunction with its Q4 2024 financial results release.

What is ALX Oncology's main business focus?

ALX Oncology is a clinical-stage biotech company developing therapies that boost the immune system to treat cancer and extend patients' lives.

What stock exchange is ALXO listed on?

ALX Oncology (ALXO) is listed on the Nasdaq stock exchange.
Alx Oncology Holdings Inc

NASDAQ:ALXO

ALXO Rankings

ALXO Latest News

ALXO Latest SEC Filings

ALXO Stock Data

297.82M
120.03M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO